Notable Labs, Ltd.

Equities

NTBL

IL0012002452

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 11:42:47 23/05/2024 pm IST			5-day change	1st Jan Change
0.802 ^USD	-16.46%		-11.11%	-49.21%

16/05	Chardan Cuts Price Target on Notable Labs to $5 From $7 on Higher Expected Share Count Dilution, Keeps Buy Rating	MT
15/04	Chardan Cuts Price Target on Notable Labs to $7 From $9, Keeps Buy Rating	MT

Vascular Biogenics Ltd. Announces the Resignation of Dan Gelvan from the Board of Directors

November 08, 2016 at 02:37 am IST

Vascular Biogenics Ltd. announced the resignation of Dan Gelvan from the company's Board of Directors. Dr. Gelvan's resignation did not result from any disagreement with the company on any matter relating to the Company's operations, policies or practices.

Latest news about Notable Labs, Ltd.

Chardan Cuts Price Target on Notable Labs to $5 From $7 on Higher Expected Share Count Dilution, Keeps Buy Rating	16/05	MT
Chardan Cuts Price Target on Notable Labs to $7 From $9, Keeps Buy Rating	15/04	MT
Chardan Cuts Price Target on Notable Labs to $7 From $9 on Higher Projected Future Share Count, Keeps Buy Rating	15/04	MT
Notable Labs, Ltd. Presents the Design Plan for the Ppmp-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024	10/04	CI
Notable Labs Presentation of Data Related to Innovations in the Use of Cryopreserved Samples in the PPMP Assay At AACR 2024 Expands the Potential of the Platform	08/04	CI
Notable Labs, Ltd. Advances Volasertib Phase 2 Program Utilizing Proprietary Predictive Precision Medicine Platform-Guided Enrollment	22/02	CI
Top Premarket Gainers	09/01	MT
JMP Securities Cuts Notable Labs' Price Target to $9 From $13, Keeps Market Outperform Rating	19/12	MT
Notable Labs, Ltd. and CicloMed LLC Announces Initial Safety and Efficacy Data of Fosciclopirox and the Performance of PPMP	18/12	CI
Transcript : Notable Labs, Inc., Vascular Biogenics Ltd. - M&A Call	17/23/17
Vascular Biogenics, Notable Labs Complete Merger	17/23/17	MT
Vascular Biogenics Ltd.(NasdaqCM:VBLT) dropped from NASDAQ Composite Index	16/23/16	CI
Notable Labs, Inc. completed the acquisition of Vascular Biogenics Ltd. from Aurum Ventures MKI Ltd. and others in reverse merger transaction.	16/23/16	CI
Vascular Biogenics Ltd. Approves Board Appointments	13/23/13	CI
Vascular Biogenics Ltd. has Changed its Name to Notable Labs, Ltd	13/23/13	CI
Vascular Biogenics Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/23/14	CI
Vascular Biogenics Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	16/23/16	CI
Vascular Biogenics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	14/23/14	CI
An unknown buyer completed the acquisition of Manufacturing facility in Modiin, Israel and certain related assets from Vascular Biogenics Ltd..	09/23/09	CI
Aleph Farms Limited completed the acquisition of manufacturing facility in Israel from Vascular Biogenics Ltd..	09/23/09	CI
Sector Update: Health Care Stocks Finishing with Small Rise	24/23/24	MT
Sector Update: Health Care	24/23/24	MT
Top Midday Gainers	24/23/24	MT
Transcript : Notable Labs, Inc., Vascular Biogenics Ltd. - M&A Call	23/23/23
Vascular Biogenics, Notable Labs Sign Merger to Form Nasdaq-Listed Therapeutic Platform Company	23/23/23	MT

Chart Notable Labs, Ltd.

Duration

Period

More charts

Company Profile

Notable Labs Ltd, formerly Vascular Biogenics Ltd, is an Israel-based clinical-stage biopharmaceutical company committed to developing next-generation, targeted medicines for difficult-to-treat medical conditions. The Company has created a pipeline of therapeutics that address cancer and immune-inflammatory diseases with the goal of significantly improving patient outcomes and overcoming the limitations of approved treatments. The Company's product candidates are built off of two platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.96 USD

Average target price

7 USD

Spread / Average Target

+629.17%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
NOTABLE LABS, LTD.	-49.21%	86.58L
VERTEX PHARMACEUTICALS INCORPORATED	+10.51%	12TCr
REGENERON PHARMACEUTICALS, INC.	+12.16%	11TCr
BIONTECH SE	-4.56%	2.47TCr
ARGENX SE	-2.33%	2.2TCr
GENMAB A/S	-6.03%	1.93TCr
BEIGENE, LTD.	-13.45%	1.76TCr
WUXI APPTEC CO., LTD.	-40.50%	1.73TCr
NEUROCRINE BIOSCIENCES, INC.	+6.05%	1.4TCr
SAREPTA THERAPEUTICS, INC.	+30.58%	1.21TCr

Bio Therapeutic Drugs